NasdaqGS:GILDBiotechs
Did Gilead’s (GILD) Strong Quarter, Bigger Dividend and Yescarta Win Just Redefine Its Story?
In February 2026, Gilead Sciences reported higher fourth-quarter and full-year 2025 revenue and earnings, raised its quarterly dividend to US$0.82 per share, completed a multi-year US$4.15 billion buyback program, and received FDA approval to remove key prescribing limitations for its Yescarta CAR T-cell therapy in certain lymphoma patients.
Together, these moves highlight Gilead’s emphasis on returning cash to shareholders while trying to widen its oncology footprint alongside its...